NCT04108897

Analysis of the Microbiome in Rosacea

• Status: Active Not Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Johns Hopkins University · Academic / Other
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Accepted

Summary

The skin and gut microbiome of rosacea patients differs from individuals without rosacea and that the microbiome suffers from unique derangements in rosacea patients following antibiotic therapy. This study was proposed to examine microbial signatures of the skin and gut microbiome in patients with moderate to severe rosacea and to identify differences between microbe communities in patients with rosacea and volunteers without rosacea using 16S ribosomal ribonucleic acid (rRNA) polymerase chain reaction (PCR) amplification, sequencing and computational phylogenetics and to assess alterations in the gut and skin microbiota of patients with moderate to severe rosacea in response to varying formulations of antimicrobial treatment.

Conditions

• Rosacea

Interventions

Type	Name	Description
DRUG	Doxycycline	The investigators will administer doxycycline to rosacea patients according to the dose of patients' assigned study arm.
DRUG	Ivermectin Topical	1% topical ivermectin.

Timeline

• Start date: 2019-09-17
• Primary completion: 2027-09-01
• Completion: 2027-09-01
• First posted: 2019-09-30
• Last updated: 2025-06-13

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study